B&K CORP-B (02396) slumped more than 12%, hitting a low of HK$18.6 to set a new record low since its listing, and has now halved from its initial public offering price of HK$38.2. As of the time of writing, the stock was down 11.77%, trading at HK$18.67, with a turnover of HK$7.462 million.

B&K CORP-B is a biopharmaceutical company focused on the discovery, development, and commercialization of wound healing therapies. As of December 5, 2025, the company's pipeline includes ten candidate products, seven of which are PDGF-based candidate drugs, covering two core products: Pro-101-1 and Pro-101-2.

Financially, the company has not yet generated any revenue from product sales. In 2023, 2024, and for the period ended September 30, 2025, the company reported net losses of RMB 110 million, RMB 210 million, and RMB 130 million, respectively. The vast majority of these net losses were attributable to research and development expenses and administrative costs.